Lepodisiran Explained

Drug Name:	Lepodisiran
Synonyms:	LY3819469; LY-3819469
Legal Status:	Investigational
Cas Number:	2808361-18-2
Unii:	X4BE7S8PN9

Lepodisiran (LY3819469) is a small interfering RNA that was developed to reduce lipoprotein(a) in people at risk of cardiovascular disease. It was developed by Eli Lilly and Company.^{[1] [2]}

Notes and References

1. Nissen . Steven E. . Linnebjerg . Helle . Shen . Xi . Wolski . Kathy . Ma . Xiaosu . Lim . Shufen . Michael . Laura F. . Ruotolo . Giacomo . Gribble . Grace . Navar . Ann Marie . Nicholls . Stephen J. . Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial . JAMA . 12 November 2023 . 330 . 21 . 2075–2083 . 10.1001/jama.2023.21835 . 37952254 . 10641766 . 0098-7484 .
2. Boyanovsky . Boris B. . Lipoprotein(a) Lowering Medications: Another Step Forward in Atherosclerosis Management . Journal of Cardiovascular Pharmacology . July 2023 . 82 . 1 . 32–36 . 10.1097/FJC.0000000000001438. 37192439 . free .